Skip to main content

Table 2 Downregulation of identified one-target enzymes to reduce the viral biomass growth rate (VBGR) when using DMEM and Ham’s medium

From: Fuzzy optimization for identifying antiviral targets for treating SARS-CoV-2 infection in the heart

Enzyme

DMEM

HAM

Metabolic pathway

No. drugs

\(\eta_{CV}^{TR}\)

\(\eta_{MD}^{TP}\)

VBGR

vATP

\(\eta_{CV}^{TR}\)

\(\eta_{MD}^{TP}\)

VBGR

vATP

NME4

0.989

0.289

0.022

38

0.904

0.301

0.192

38

Biosynthesis of pyrimidine deoxyribonucleotides from CTP

23

MMUT

0.989

0.289

0.022

38

0.999

0.283

0.003

38

Diseases resulting from mitochondrial beta oxidation

2

PLD2

0.973

0.313

0.055

38

0.904

0.343

0.193

38

Role of phospholipids in phagocytosis

2

PTDSS1

0.962

0.301

0.075

38

0.887

0.306

0.227

38

Glycerophospholipid biosynthesis

1

GOT2

0.949

0.275

0.103

38

0.897

0.283

0.206

38

Alanine and aspartate metabolism

NA

GUK1

0.946

0.316

0.108

38

0.871

0.298

0.258

38

Abacavir pathway

3

GMPR2♣

0.946

0.304

0.109

38

1.0

0.383

0

38

Nucleotide salvage

1

HIBADH

0.934

0.281

0.132

38

0.986

0.288

0.028

38

Leucine, isoleucine and valine metabolism

1

RENBP

0.932

0.311

0.135

38

0.994

0.329

0.012

38

Synthesis of substrates in N-glycan biosynthesis

1

DCK

0.917

0.301

0.166

38

0.941

0.315

0.118

38

Gemcitabine pathway

10

FH

0.901

0.280

0.198

38

0.908

0.270

0.184

38

TCA cycle in senescence

4

HADH*

0.739

0.389

0.521

38

0.25

0.352

1.5

38

Beta-oxidation of fatty acids

4

ECHS1*

0.678

0.373

0.644

38

0.957

0.371

0.086

38

Beta-oxidation of fatty acids

5

CRLS1

0.25

0.685

0

0.001

0.25

0.655

0

0.001

Metabolism of glycerolipids and glycerophospholipids

NA

MGLL♣

0.25

0.669

0

0.001

0.25

0.655

0

0.001

Triglyceride metabolism

NA

LSS

0.25

0.664

0

0.001

0.021

0.288

1.5

3.138

Cholesterol biosynthesis

2

SQLE

0.25

0.664

0

0.001

0.021

0.288

1.5

3.138

Cholesterol biosynthesis

4

GK

0.25

0.647

0

0.001

0.25

0.630

0

0.001

Glycerol degradation

NA

MVK

0.25

0.642

0

0.001

0.021

0.288

1.5

3.138

Cholesterol biosynthesis

1

MVD

0.25

0.642

0

0.001

0.021

0.288

1.5

3.138

Cholesterol biosynthesis

NA

PMVK

0.25

0.642

0

0.001

0.021

0.288

1.5

3.138

Cholesterol biosynthesis

NA

PGS1

0.25

0.635

0

0.001

0.25

0.645

0

0.001

Glycerophospholipid biosynthetic pathway

NA

SC5D

0.25

0.634

0

0.001

0.021

0.288

1.5

3.138

Cholesterol biosynthesis

NA

PCYT1A♣

0.25

0.622

0

0.001

0.25

0.620

0

0.001

Acetylcholine synthesis

3

PGK1♣

4.4E-16

0.239

1.5

0.039

0.904

0.406

0.192

38

Glycolysis in senescence

5

BPGM♣

–

–

–

–

0.904

0.403

0.192

38

Glycolysis

NA

GAPDH♣

–

–

–

–

0.904

0.411

0.192

38

Glycolysis

9

ENO1♣

–

–

–

–

0.904

0.399

0.192

38

Glycolysis

6

  1. The complex enzymes HADH* and ECHS1* comprise three genes each; HADH* consists of HADHA, EHHADH, and HADH, and ECHS1* consists of HADHA, ECHS1, and EHHADH. The symbol ♣ indicates a duplicate enzyme (e.g., GAPDH). The terms \(\eta_{CV}^{TR}\) is the cell viability grade for treated HV cells and \(\eta_{MD}^{TP}\) is the metabolic deviation grade to evaluate fuzzy similarity and fuzzy dissimilarity of TR and PH cells relative to their HV and HT templates, respectively. VBGR and vATP represent viral biomass growth rate and ATP production rate of treated HV cells. No. Drugs denotes the number of drugs retrieved from DrugBank (https://www.drugbank.ca/) that modulate each gene, and NA indicates as not available from DrugBank.
Back to article page

BMC Bioinformatics

ISSN: 1471-2105

Contact us